Genetic and pathologic studies have associated angiotensin-converting enzyme (ACE) with Alzheimer disease. Previously, we and others have reported that ACE degrades in vitro the amyloid β-protein (Aβ), a putative upstream initiator of Alzheimer disease. These studies support the hypothesis that deficiency in ACE-mediated Aβ proteolysis could increase Alzheimer disease risk and raise the question of whether ACE inhibitors, a commonly prescribed class of anti-hypertensive medications, can elevate Aβ levels in vivo. To test this hypothesis, we administered the ACE inhibitor captopril to two lines of APP transgenic mice harboring either low levels of Aβ or high levels of Aβ with associated plaque deposition. In both models, we show that captopril does not affect cerebral Aβ levels in either soluble or insoluble pools. Furthermore, we find no change in plaque deposition or in peripheral Aβ levels. Data from these Alzheimer models suggest that captopril and similar ACE inhibitors do not cause Aβ accumulation in vivo.
Introduction
Alzheimer disease (AD) is characterized by the progressive accumulation and deposition into plaques of the pathogenic amyloid β-protein (Aβ) in various brain regions, leading to impairments in memory, language, cognition and behavior. Brain levels of soluble Aβ species correlate with the presence and extent of AD-type dementia (Lue et al., 1999) . In familial cases of AD, mutations in genes encoding the β-amyloid precursor protein (APP) or the presenilins cause accelerated accumulation and toxicity of Aβ, resulting in an early onset and aggressive form of the disease. Typical, late-onset AD cases are of unknown etiology. However, several studies highlight decreased Aβ degradation (Caccamo et al., 2005) or impaired Aβ transport (Shibata et al., 2000) in aging and in AD, leading to the hypothesis that deficits in Aβ clearance spur disease progression. One mechanism of Aβ clearance is the direct degradation of the peptide by proteases residing within the brain. Several Aβ-degrading enzymes have been shown, by knockout and overexpression studies, to regulate the levels of cerebral Aβ. These include neprilysin (NEP) (Iwata et al., 2001) , insulin-degrading enzyme (Farris et al., 2003; Miller et al., 2003) and the endothelin-converting enzymes (Eckman et al., 2003) . The serine protease plasmin has been shown to promote Aβ clearance from the brain (Melchor et al., 2003) , though genetic deficiency does not change steady-state murine Aβ metabolism in vivo (Tucker et al., 2004) . As more Aβ-degrading proteases are identified -recently including matrix metalloproteinase-9 (Yan et al., 2006) and the mitochondrial presequence peptidase (Falkevall et al., 2006 ) -novel pathways to manipulate Aβ clearance are being proposed. Supporting a potential therapeutic role for Aβ proteolysis in AD, overexpressing Aβ-degrading proteases has been found to modulate the progression of Aβ deposition and neuropathology in a mouse model of AD (Leissring et al., 2003) .
Angiotensin-converting enzyme (ACE) is a zinc metalloprotease containing two homologous proteolytically active domains. A major function of ACE is to regulate blood pressure by cleaving angiotensin I to angiotensin II and inactivating bradykinin (Coates, 2003) . Small molecule competitive inhibitors of ACE have been developed to prevent vasopeptide proteolysis, which has proven to be a successful strategy for the management of hypertension. A link between ACE and AD was first hypothesized by human genetic studies, which have found both single nucleotide polymorphisms (Katzov et al., 2004) and an intronic insertion (I)/ deletion (D) polymorphism within the ACE gene that associate with AD (Lehmann et al., 2005) . The I allele has been associated
